CervoMed Inc
CRVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$24.63M
Close$
$0.91
65.8% downside
Current Fair Value
65.8% downsideOvervalued by 65.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $24.63 Million |
|---|---|
| Enterprise Value | $16.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.98 |
| Beta | -4.42 |
| Outstanding Shares | 9,258,319 |
Return
| Return on Equity | -282.94% |
|---|---|
| Return on Assets | -198.75% |
| Return on Invested Capital | -239.75% |
Valuation & Multiples
| P/E Ratio | -0.81 |
|---|---|
| PEG | -1.3 |
| Price to Sales | - |
| Price to Book Ratio | 2.66 |
| Enterprise Value to Revenue | 7.99 |
| Enterprise Value to EBIT | -0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$71,429
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$42,857
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.11%▼ 5.62% |
|---|---|
| Total Invested | $6.97M▼ 68.57% |
| Investors Holding | 36▼ 13.00% |
ESG Score
No data
About CervoMed Inc
18 employeesdiffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company ...